ReviewCell biochemistry and biophysics2026
Emerging Dual Roles of ALKBH5 in Ischemia-reperfusion Injury: Mechanisms and Therapeutic Implications.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ischemia-reperfusion injury (IRI) is a critical pathological process affecting multiple organs, including the heart, brain, kidney, and liver. Recent studies have highlighted the dual roles of AlkB homolog 5 (ALKBH5), an N6-methyladenosine (m⁶A) RNA demethylase, in regulating cellular responses to IRI through epigenetic mechanisms. This review synthesizes current evidence on ALKBH5 involvement in metabolic reprogramming, autophagy, apoptosis, pyroptosis, and inflammation across organ-specific IRI models. We establish a unifying framework in which ALKBH5 functions as a double-edged sword, exerting either protective effects (such as sirtuin 1 (SIRT1) activation in the heart) or detrimental outcomes (such as tricarboxylic acid (TCA) cycle suppression), depending on tissue-specific microenvironments, disease stage dynamics, and downstream effector crosstalk (e.g., TCA cycle, SIRT1, PANoptosis). Despite its therapeutic potential, challenges in translation persist due to ALKBH5’s bidirectional effects and the lack of tissue-specific delivery systems. Future research should aim to resolve these controversies through advanced techniques such as single-cell m⁶A epitranscriptomics and develop spatiotemporally targeted modulators for precise intervention.
Indexed as
Identifiers
41160375What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.